Both cellular systems were derived from isogenic mice engineered to develop pancreatic cancer lesions using pdx1-CRE mouse models with pancreas-specific expression of constitutively active KRAS (LSL-KRASG12D) and either p53R270H (KPCR270H) or p53R172H (KPCR172H). This evidence concerns the gene KRAS and pancreatic neoplasm.